Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 27–Oct 4, 2026)

· 2 min read

No FDA decision dates fall in this week, so the calendar belongs to trials: seven company-led studies have estimated primary completion dates, among them IBRX’s BCG combination in bladder cancer, ARWR’s ARO-DIMERPA in mixed hyperlipidemia and JAZZ’s zanidatamab combination. On the financing side, VKTX filed $275M of convertible notes, and it was also last week’s biggest gainer, up 36%.

🧪 Trial Catalysts & Milestones

  • IBRX, 2026-09-30: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Registry
  • BIIB, 2026-09-30: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden Registry
  • ARWR, 2026-09-30: Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia Registry
  • JAZZ, 2026-09-30: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Registry
  • IBRX, 2026-10-01: A Study to Assess Anktiva in Patients With Long Covid-19. Registry
  • CORT, 2026-10-01: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Registry
  • BHVN, 2026-10-01: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Registry

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • SLDB: Phase 1, Phase 2, Active Trial in 18 days, score 62/100
  • EWTX: N/A, Active Trial in 3 days, score 52/100
  • SNDX: Phase 1, Recruiting in 4 days, score 50/100

💸 Dilution Watch: New Financing Filings

  • VKTX: convertible notes $275M (424B5, 2026-09-25) EDGAR
  • IMCC: registered direct offering (424B5, 2026-09-24) EDGAR
  • BMRA: shelf registration (S-3, 2026-09-24) EDGAR
  • GRML: ATM program (424B5, 2026-09-23) EDGAR
  • GRML: registered direct offering (424B5, 2026-09-23) EDGAR

Full Dilution Watch table →

📈 Last Week’s Biggest Gainers

  • VKTX +35.67% (volume 17.9x average)
  • TWST +16.11% (volume 2.0x average)
  • TNGX +14.33% (volume 2.4x average)
  • IBRX +9.94% (volume 2.1x average)
  • BRVE +8.90% (volume 0.7x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.